The drug, which Lilly in-licensed four years ago and is designed to inhibit a protein known as P2X7, did not meet the company ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Shares in Avidity Biosciences (NASDAQ: RNA) soared by 42% in the week to Friday morning following the announcement of a ...

Before being discontinued, the P2X7 receptor blocker had cleared a master protocol study in chronic pain, though Eli Lilly ...

Takeda tightened its pipeline in the third quarter. Innovent Biologics reported a head-to-head win against semaglutide in a Chinese phase 3 trial. | Takeda tightened its pipeline in the third quarter.

Welcome back to Changing Faces, in our final round-up for August and September there are plenty of Board appointments to ...

The use of immunotherapy in patients with various types of cancer has led to dramatic increases in survival. Increased median ...

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...

The company's outlook for the rest of the year was rosier than in the previous quarter, when it announced a cost-cutting plan ...

In parallel with mazisotine’s shelving, Lilly added a phase 1 NaV1.8 inhibitor from its SiteOne Therapeutics acquisition to ...

As momentum for Biogen’s newer drugs for neurological disorders builds at a slow and steady pace, it appears that the company ...